アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。

私たちはウェブサイトをできるだけ使いやすくするために、クッキーを使用しています。

クッキー・ポリシーでは、使用するクッキーをオプトアウトする方法について説明しています。

クッキーの設定を変更しないままでいる場合、このポリシーに同意しているとみなされます。

続ける 続ける

お問い合わせは電話 +81-(0)3-6231-0940 または メールでどうぞ

  • アカウント
  • ログアウト
ログイン または 新規登録

Welcome

ログイン または

すでにアカウントをお持ちですか?

新規登録
カート
クイック・オーダー
Abcam homepage

  • 研究用製品
    製品タイプ別
    一次抗体
    二次抗体
    イムノアッセイキット・試薬
    細胞・組織イメージング
    細胞・バイオケミカルアッセイ
    タンパク質・ペプチド
    製品タイプ別
    プロテオミクス
    アゴニスト・アクチベータ-・アンタゴニスト・インヒビター
    細胞株・ライゼート
    miRNA マルチプレックス・アッセイキット
    マルチプレックス・アッセイ
    研究分野別
    癌
    循環器系
    細胞生物学
    エピジェネティクス
    メタボリズム
    発生生物学
    研究分野別
    免疫学
    微生物学
    脳神経科学
    シグナル伝達
    ステムセル
  • 診断と治療のソリューション
    カスタム・ソリューション & パートナーシップ

    あなたの診断法や治療法を発展させるための、カスタム抗体開発およびコマーシャル・パートナーシップ

    私たちと共にカスタム・ソリューションを創造する

    私たちとパートナーになる

  • サポート
    サポートハブ

    研究のためのサポートとアドバイス

    サポートハブを表示

    プロトコール

    実験のステップごとの詳細

    プロトコールを表示

  • イベント
    • イベント・カレンダー
    • 癌
    • 循環器
    • エピジェネティクス&核内情報
    • 免疫学
    • ニューロサイエンス
    • ステムセル
    • 展示会
    • ウェビナー
    最新のイベント情報

    世界中でアブカムが主催する研究会やセミナーの日程、内容、演者など

    イベント・カレンダー

  • パスウェイ
    細胞シグナル伝達パスウェイ

    すべてのパスウェイを見る

    インタラクティブ・パスウェイを見る

  • ブログ
    アブカム・ブログ

    最新の情報はこちら.

    • キャンペーン
    • 製品情報
    • 技術情報
製品:研究分野別
  • 癌
  • 循環器
  • 細胞生物学
  • エピジェネティクス&核内情報
  • 発生
  • 免疫学
  • 代謝関連
  • 感染症
  • ニューロサイエンス
  • シグナル伝達
  • ステムセル

Abcam news

Jul-2020

Cancer Research UK and Abcam launch custom partnership to accelerate cancer research

Mar-2020

Abcam triumphs with industry award for knockout antibody validation success

Jan-2020

Abcam Expands Cell Engineering Capabilities Through Asset Purchase of Applied StemCell’s Gene Editing Platform and Oncology Product Portfolio

Jan-2020

Abcam’s new CRISPR-Cas9 cell lines for target identification, validation and pathway discovery

Jan-2020

New JBC manuscript promotes industry-leading best practice guidance on antibody validation via Western blotting

Jan-2020

Abcam appoints Michael Baldock as Chief Financial Officer

Jan-2020

Abcam announces successful acquisition of Expedeon’s Proteomics and Immunology business, enhancing its conjugation capability

Dec-2019

Abcam and SomaServe announce comprehensive partnership to realise the potential of PolyNaut® ‘bionic’ nanoparticles for delivery to live cells

Dec-2019

Abcam Honoured As One Of The UK’s Best Places To Work In 2020; A Glassdoor Employees’ Choice Award Winner

Nov-2019

Abcam delivers outstanding performance in new Biocompare antibody market report

Nov-2019

Scientists poised to unlock their understanding of autophagy with new antibody-based insights

Nov-2019

Abcam agrees to acquire Expedeon’s Proteomics and Immunology business, expanding offerings into the fast-growing conjugation segment

Nov-2019

Abcam and BrickBio announce a partnership to incorporate conjugation-ready sites into recombinant antibodies across Abcam's portfolio

Nov-2019

Engineered knockout cell lysates for reproducible proteomic analysis

Jul-2019

Abcam Enters Cell Editing Market Through Acquisition of EdiGene’s Knock-out Cell Lines and Lysates Portfolio

May-2019

New tissue clearing kits and reagents for faster, accurate 3D imaging

Apr-2019

NanoString and Abcam Enter Commercial Partnership to Provide Expanded Menu of Antibodies for GeoMx Digital Spatial Profiler

Mar-2019

Abcam collaborates with Visikol to develop new tools for improved tissue clearing and 3D imaging

Mar-2019

Abcam wins the UK-China Business award

Feb-2019

Abcam moves to new purpose-built global headquarters

Feb-2019

Dr Michael Weiner wins CiteAb’s 2019 Lifetime achievement award

Jan-2019

Abcam expands custom services capabilities with the acquisition of Calico Biolabs

Jan-2019

Abcam and the LouLou Foundation partner to develop key research tools for CDKL5 deficiency disorder

Dec-2018

QIAGEN (Suzhou) and Abcam sign strategic MoU collaboration agreement to co-develop companion diagnostic (CDx) and in vitro diagnostic (IVD) reagents and kits for the Chinese market

Dec-2018

Abcam 'Most Admired Company' award

Oct-2018

Abcam appoints Cheri Walker, PhD, as Senior Vice President, Corporate Development

Oct-2018

New PBS-only antibodies enable more flexible research

Jul-2018

Abcam Merck collaboration produces new PD-L1 antibody for immuno-oncology research

Jun-2018

Congratulations to Alan Hirzel, winner of European Mediscience Awards Chief Executive of the year award

Apr-2018

Abcam and Shuwen Biotech sign strategic MoU to establish global alliance for companion diagnostic (CDx) kit development

Feb-2018

New CatchPoint® SimpleStep® ELISA fluorescent 90-minute assay

Feb-2018

Introducing FirePlex®-HT High-throughput Multiplex Immunoassays – Delivering More Data from Precious Samples

Feb-2018

Abcam and Molecular Devices announce strategic collaboration

Jan-2018

Abcam wins another CiteAb award

Jan-2018

Abcam signs exclusive license agreement with Roche

Aug-2017

Abcam and TTP Labtech collaborate to develop sol-R reagent kits

Jul-2017

The University of Bath enters licensing agreement with Abcam to develop fluorescent detection probe kit for sugar-damaged proteins

Jun-2017

Abcam announces first international Epigenetics conference in South Korea

Jan-2017

Abcam wins two CiteAb awards

Nov-2016

Abcam wins Best Careers Website at the In-house Recruitment Awards

Jul-2016

New multiplex immunoassays with Firefly® particle technology

Apr-2016

Abcam enables faster drug and biomarker discovery with immunoassay research suite

Feb-2016

Congratulations to Jonathan Milner, winner of CiteAb’s Lifetime achievement award

Nov-2015

Abcam offers direct service to Singapore as part of deepening commitment to Asia-Pacific researchers

Nov-2015

Abcam acquires AxioMx to access new growth opportunities and extend antibody leadership

Oct-2015

Abcam’s new anti-PD-L1 antibody enables deeper insights into cancer immunology research

Sep-2015

Abcam raises antibody validation standards to improve quality for life science researchers

Jun-2015

Appointment of Chief Legal Officer and Company Secretary

Jun-2015

Abcam launches multiplex miRNA profiling assays

Jan-2015

Abcam signs exclusive partnership agreement with A*STAR's Institute of Molecular and Cell Biology

Dec-2014

Sue Harris appointed as non-Executive Director on Abcam Board

Dec-2014

Abcam appoints Yvonne Chien as Chief Digital Officer

Nov-2014

Abcam wins 'Best Use of Digital Media' at Life Science Industry Awards

Sep-2014

Abcam licenses novel Ceefourin inhibitors of multidrug resistance protein 4 from Australia's Children's Cancer Institute

Sep-2014

Abcam plc announces appointment of new CEO and Board changes

Sep-2014

Abcam and Cell Marque sign global strategic marketing agreement for IVD IHC RabMAb® antibodies

Sep-2014

Abcam introduces exclusive range of highly validated antibody conjugates

Jun-2014

Abcam's CEO wins Mediscience award

Mar-2014

Abcam introduces Alexa Fluor® 680/790 secondary antibodies for fluorescent western blotting

Feb-2014

Abcam Announces Winner of 15 Discoveries Contest

Jan-2014

Abcam to open office in Shanghai, China

Dec-2013

Abcam wins 'Most Admired Company' award

Nov-2013

Abcam Introduces Alexa Fluor Secondary Antibodies

Oct-2013

Abcam Named AIM Company of the Year

Sep-2013

Abcam Launches SimpleStep ELISA Kits

Jun-2013

Abcam appoints Alan Hirzel as Chief Marketing Officer

Apr-2013

Abcam Welcomes Students from Cambridge Regional College

Mar-2013

Abcam donates an additional £45,000 to local charities

Dec-2012

Abcam helps contribute to growth of hi-tech sector in Cambridge, UK

Nov-2012

We have reached 100,000 products

Oct-2012

HRH The Duke of York visits Abcam to see the Cambridge Phenomenon in action

Sep-2012

Rabbit monoclonal antibodies, available from Abcam following acquisition of Epitomics

Jan-2012

New range of Biochemicals now available from Abcam

Sep-2011

Abcam acquires Ascent Scientific, a specialist provider of biochemicals

May-2011

Abcam acquires MitoSciences in deal which enhances immunoassay portfolio

Nov-2010

Jonathan Milner wins Entrepreneur of the Year award.

Jul-2010

Abcam's Jonathan Milner wins CEO of the Year

Jul-2010

300th employee hired

Mar-2010

Abcam wins 'Business of the Year 2009' at the Business Weekly East of England Awards.

Feb-2010

Abcam founder wins 'CEO of the Year' at Quoted Company Awards 2010

Jan-2010

Abcam and Cambridge Design Partnership develop innovative labeling solution

Oct-2009

Abcam named 'Company of the Year' at 2009 AIM Awards

Jun-2009

Abcam’s expansion continues with its fourth move on the Cambridge Science Park

Nov-2008

Winners of tenth anniversary competition announced

Jul-2008

200th employee hired

May-2008

Licensing deal signed with Tepnel Life Sciences

Mar-2008

Grand setting for Japanese sub-dealer meetings

Nov-2007

Automated system to expand monoclonal production

Nov-2007

Abcam and leading antibody producer collaborate to make 12,000 rabbit polyclonals

Nov-2007

CLC bio customized software supports Abcam's monoclonal development capability

Nov-2007

Jeffrey Iliffe appointed as Chief Financial Officer

May-2007

Same day delivery in Cambridge UK

Mar-2007

Abcam to partner in the EPITRON project

Jan-2007

$2 to Médecins Sans Frontières for every new registration

Jul-2006

Extra Abpoints introduced for first Abreviews

Jul-2006

Appointment of Non-Executive Directors

Jun-2006

Winner of Best Newcomer in the European Mediscience awards

May-2006

Better antibodies, faster

Feb-2006

Winner of Private Company of the Year, Business Weekly East of England Business Awards 2005

Feb-2006

20,000+ products, 1,300 new lysates, Abpromise stats, Abupdate & news

Jan-2006

Fast Abpromise support, free loading control samples, Abupdate & news

Nov-2005

Search filter, conjugated loading controls, Abupdate & news

Sep-2005

Top forty position, Sunday Times Microsoft Tech Track

May-2005

US office on the move

Apr-2005

Queen's Award at first attempt

Apr-2005

More space

Dec-2004

A faster service

Oct-2004

First place in Deloitte's Fast 50

Sep-2004

50th employee hired

Sep-2004

Top forty position, Sunday Times Microsoft Tech Track

Jun-2004

Jim Warwick becomes Managing Director (Abcam Ltd)

Feb-2004

Collaboration deal struck with Purely Proteins

Jan-2004

A New Year's Honour

Dec-2003

High growth status recognised again, this time nationally

Oct-2003

Success in Deloitte's Regional Technology Fast 50

Sep-2003

Top twenty position, Sunday Times Arm Tech Track

Jul-2003

British royalty visits Abcam

May-2003

First overseas office established

Apr-2003

Jim Warwick (Technical Director) becomes full-time

Mar-2003

CEN Business Excellence Awards winner

Mar-2003

25th employee hired

Feb-2003

On the move again

Nov-2002

Deloitte Top 50 regional winner

Aug-2002

FedEx tie-up boosts customer support services

Jun-2001

Technical Director appointed

May-2001

UK Online for Business Award, highly commended

Oct-2000

CEN Millennium Business Excellence Awards finalist

May-2000

10th employee hired

Apr-2000

Finance Director appointed

Mar-2000

New premises on the Cambridge Science Park

Oct-1999

First (of many) awards

Oct-1998

Open for business

技術情報や製品情報をメールで受け取る 登録
製品・研究分野別
  • 癌
  • 循環器
  • 細胞生物学
  • 発生
  • エピジェネティクス&核内情報
  • 免疫学
  • メタボリズム
  • 感染症
  • ニューロサイエンス
  • シグナル伝達
  • ステムセル
製品・タイプ別
  • 一次抗体
  • 二次抗体
  • バイオケミカルズ
  • アイソタイプ・コントロール
  • マルチカラー・セレクター
  • キット
  • ローディング・コントロール
  • ライゼート
  • ペプチド
  • タンパク質
  • スライド
  • タグ抗体・細胞マーカー
  • その他試薬
サービス&サポート
  • サポート
  • よくあるお問い合わせ
  • プロトコール&トラブルシュート
  • ご購入に関して
  • お問い合わせフォーム
  • トレーニング
アブカムについて
  • 企業ウェブサイト
  • 投資家の皆様へ
  • 企業情報
  • 採用情報
  • アブカムについて
イベント
  • 展示会
  • カンファレンス
ブログ

ブログを読む

International websites
  • abcam.com
  • abcam.cn

Join with us

  • LinkedIn
  • facebook
  • Twitter
  • YouTube
  • Terms of sale
  • Website terms of use
  • Cookie policy
  • Privacy policy
  • Legal
© 1998-2020 Abcam plc. All rights reserved.